NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis $1.49 +0.06 (+4.13%) Closing price 03:59 PM EasternExtended Trading$1.51 +0.02 (+1.48%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Allarity Therapeutics Stock (NASDAQ:ALLR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allarity Therapeutics alerts:Sign Up Key Stats Today's Range$1.36▼$1.4950-Day Range$1.04▼$1.6852-Week Range$0.77▼$2.35Volume187,935 shsAverage Volume228,176 shsMarket Capitalization$23.69 millionP/E RatioN/ADividend YieldN/APrice Target$9.75Consensus RatingHold Company Overview Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval. The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials. These programs explore combinations of targeted therapy and standard chemotherapy in colorectal, ovarian and breast cancers. Allarity’s diagnostic platform supports these efforts by employing gene expression signatures to match treatments with tumor biology, offering a more personalized approach than conventional “one‐size‐fits‐all” regimens. Founded in 2015 as OncoBay, the company rebranded to Allarity Therapeutics in 2020 to reflect its expanded precision medicine strategy. Headquartered in Copenhagen, Denmark, Allarity maintains a U.S. presence in Cambridge, Massachusetts, to facilitate clinical collaborations and regulatory interactions. Under the leadership of CEO Christian M. Vedelsdal and an experienced executive team, the company has built partnerships with research institutions and contract organizations to advance its clinical programs. Allarity serves global markets by enrolling patients across North America and Europe in its ongoing trials. The company’s outward focus on combining diagnostics with therapeutics aligns with an evolving industry trend toward more targeted and data‐driven drug development, positioning Allarity to address significant unmet needs in oncology with a precision‐guided approach.AI Generated. May Contain Errors. Read More Allarity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreALLR MarketRank™: Allarity Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 458th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingAllarity Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAllarity Therapeutics has a consensus price target of $9.75, representing about 554.8% upside from its current price of $1.49.Amount of Analyst CoverageAllarity Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Allarity Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Allarity Therapeutics are expected to decrease in the coming year, from ($0.96) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allarity Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allarity Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllarity Therapeutics has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.77% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 2.07, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently decreased by 8.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.00 News SentimentAllarity Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Allarity Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ALLR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.01% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by Institutions11.53% of the stock of Allarity Therapeutics is held by institutions.Read more about Allarity Therapeutics' insider trading history. Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLR Stock News HeadlinesAllarity Therapeutics, Inc.: Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple CancersMay 16 at 3:10 PM | finanznachrichten.deAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple CancersMay 15, 2026 | globenewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 19 at 1:00 AM | Profits Run (Ad)Allarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026May 8, 2026 | quiverquant.comQAllarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in StockholmMay 8, 2026 | globenewswire.comAllarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing CampaignMay 5, 2026 | globenewswire.comAllarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark OfficeApril 27, 2026 | globenewswire.comAllarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall ...April 21, 2026 | markets.businessinsider.comSee More Headlines ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed this year? Allarity Therapeutics' stock was trading at $1.08 on January 1st, 2026. Since then, ALLR stock has increased by 37.9% and is now trading at $1.4890. How were Allarity Therapeutics' earnings last quarter? Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced its quarterly earnings data on Friday, May, 15th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.05. The company earned $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. When did Allarity Therapeutics' stock split? Allarity Therapeutics shares reverse split on the morning of Wednesday, September 11th 2024.The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How will Allarity Therapeutics' stock buyback program work? Allarity Therapeutics' board approved a stock repurchase plan on Monday, March 3rd 2025, which authorizes the company to buy back $5,000,000 in shares, according to EventVestor. This means that the company could buy up to 128.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its stock is undervalued. Who are Allarity Therapeutics' major shareholders? Top institutional shareholders of Allarity Therapeutics include Renaissance Technologies LLC (1.48%). How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Allarity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include AMC Entertainment (AMC), Plug Power (PLUG), Adial Pharmaceuticals (ADIL), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH) and Nuwellis (NUWE). Company Calendar Last Earnings5/15/2026Today5/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ALLR's financial health is in the Green zone, according to TradeSmith. ALLR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALLR CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees10Year Founded2004Price Target and Rating Average Price Target for Allarity Therapeutics$9.75 High Price Target$9.75 Low Price Target$9.75 Potential Upside/Downside+554.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.23 million Net MarginsN/A Pretax Margin-3,260.58% Return on Equity-109.94% Return on Assets-47.27% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio2.13 Sales & Book Value Annual Sales$320 thousand Price / Sales74.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book3.46Miscellaneous Outstanding Shares15,910,000Free Float15,459,000Market Cap$23.69 million OptionableNot Optionable Beta0.38 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ALLR) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
